Stephens analyst Ben Bienvenu noted that Hormel Foods reported Q2 results that were slightly ahead of expectations, but its FY19 EPS guidance was softer than consensus estimates. Comparing guidance to consensus, however, is complicated by the fact that some analysts were accounting for the sale of Cytosport in their estimates, while others did not, according to Bienvenu. While he keeps an Equal Weight rating on Hormel shares and is reviewing his estimate, the analyst said that management's mention of African swine fever uncertainty could pressure the shares today. In pre-market trading, Hormel shares are down $1.50, or 4%, to $37.99.